MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Omega Therapeutics Inc (NQ: OMGA )

1.530 -0.020 (-1.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 161,372
Open 1.530
Bid (Size) 1.500 (10)
Ask (Size) 1.670 (1)
Prev. Close 1.550
Today's Range 1.500 - 1.570
52wk Range 1.300 - 6.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Uber To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q2 2024
OMGA stock results show that Omega Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-48.48%
-48.48%
1 Month
-20.73%
-20.73%
3 Month
-35.03%
-35.03%
6 Month
-62.32%
-62.32%
1 Year
-58.76%
-58.76%

More News

Read More
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
From Omega Therapeutics
Via GlobeNewswire
Expert Ratings For Omega Therapeutics
Via Benzinga
4 Analysts Have This To Say About Omega Therapeutics
Via Benzinga
How Is The Market Feeling About Omega Therapeutics?
Via Benzinga
Omega Therapeutics To Participate In Two Upcoming Investor Conferences
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
From Omega Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
From Omega Therapeutics
Via GlobeNewswire
OMGA Stock Earnings: Omega Therapeutics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
From Omega Therapeutics
Via GlobeNewswire
OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
From Omega Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
The 3 Best Biotech Stocks to Buy in January 2024
Via InvestorPlace
Nvidia, Spotify Lead Five Stocks Near Buy Points
Via Investor's Business Daily
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Stock Market Skids To Start 2024 As Tesla, Apple Stumble, Mobileye Crashes: Weekly Review
Via Investor's Business Daily
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story